World News

Exact Sciences (NASDAQ:EXAS) Price Target Increased to $55.00 by Analysts at Craig Hallum

Exact Sciences (NASDAQ:EXAS) Price Target Increased to .00 by Analysts at Craig Hallum

Precise Sciences (NASDAQ:EXAS – Get Ranking) had its goal value raised by Craig Hallum from $44.00 to $55.00 in a analysis word revealed on Wednesday, The Fly studies.

A number of different brokerages have additionally weighed in on EXAS. Robert W. Baird elevated their goal value on shares of Precise Sciences from $89.00 to $92.00 and gave the inventory an outperform score in a analysis word on Wednesday. Canaccord Genuity Group elevated their goal value on shares of Precise Sciences from $70.00 to $75.00 and gave the inventory a purchase score in a analysis word on Wednesday. Citigroup elevated their value goal on shares of Precise Sciences from $35.00 to $70.00 and gave the inventory a impartial score in a analysis report on Wednesday. Credit score Suisse Group reissued a impartial score and set a $70.00 value goal on shares of Precise Sciences in a analysis report on Wednesday. Lastly, SVB Leerink elevated their value goal on shares of Precise Sciences from $70.00 to $75.00 and gave the inventory an outperform score in a analysis report on Thursday, January twelfth. Seven equities analysis analysts have rated the inventory with a maintain score and 7 have assigned a purchase score to the corporate’s inventory. Primarily based on knowledge from MarketBeat, the corporate has a consensus score of Reasonable Purchase and a consensus goal value of $70.27.

Precise Sciences Buying and selling Up 5.6 %

Shares of EXAS opened at $64.66 on Wednesday. The corporate has a present ratio of two.47, a fast ratio of two.20 and a debt-to-equity ratio of 0.72. Precise Sciences has a 12-month low of $29.27 and a 12-month excessive of $79.85. The agency has a 50-day transferring common value of $60.49 and a 200 day transferring common value of $46.24. The agency has a market capitalization of $11.49 billion, a P/E ratio of -15.77 and a beta of 1.42.

Precise Sciences (NASDAQ:EXAS – Get Ranking) final introduced its earnings outcomes on Tuesday, February twenty first. The medical analysis firm reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.18. The corporate had income of $553.00 million in the course of the quarter, in comparison with analyst estimates of $525.61 million. Precise Sciences had a unfavorable web margin of 35.73% and a unfavorable return on fairness of twenty-two.10%. Precise Sciences’s income was up 16.7% in comparison with the identical quarter final yr. Throughout the identical quarter final yr, the agency posted ($1.28) earnings per share. Promote-side analysts forecast that Precise Sciences will submit -3.67 EPS for the present yr.

Insider Exercise at Precise Sciences

In associated information, Common Counsel James Herriott offered 400 shares of Precise Sciences inventory in a transaction on Wednesday, February fifteenth. The shares had been offered at a median value of $65.59, for a complete worth of $26,236.00. Following the transaction, the overall counsel now immediately owns 9,095 shares within the firm, valued at roughly $596,541.05. The transaction was disclosed in a authorized submitting with the SEC, which is accessible via this hyperlink. In different Precise Sciences information, EVP Sarah Condella offered 1,000 shares of the enterprise’s inventory in a transaction on Monday, January ninth. The shares had been offered at a median value of $60.00, for a complete transaction of $60,000.00. Following the sale, the manager vice chairman now immediately owns 85,090 shares within the firm, valued at roughly $5,105,400. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which is offered via the SEC web site. Additionally, Common Counsel James Herriott offered 400 shares of the enterprise’s inventory in a transaction on Wednesday, February fifteenth. The inventory was offered at a median value of $65.59, for a complete transaction of $26,236.00. Following the sale, the overall counsel now owns 9,095 shares within the firm, valued at $596,541.05. The disclosure for this sale may be discovered right here. Insiders have offered a complete of 26,343 shares of firm inventory price $1,716,335 within the final three months. Insiders personal 1.30% of the corporate’s inventory.

Institutional Traders Weigh In On Precise Sciences

A number of institutional traders have not too long ago made adjustments to their positions within the inventory. Lecturers Retirement System of The State of Kentucky boosted its place in shares of Precise Sciences by 28.1% in the course of the 4th quarter. Lecturers Retirement System of The State of Kentucky now owns 49,155 shares of the medical analysis firm’s inventory price $2,434,000 after buying a further 10,786 shares within the final quarter. Macquarie Group Ltd. boosted its place in shares of Precise Sciences by 25.8% in the course of the 4th quarter. Macquarie Group Ltd. now owns 332,487 shares of the medical analysis firm’s inventory price $16,461,000 after buying a further 68,277 shares within the final quarter. Linden Thomas Advisory Providers LLC acquired a brand new place in shares of Precise Sciences in the course of the 4th quarter price $235,000. Alliancebernstein L.P. raised its stake in shares of Precise Sciences by 3.8% in the course of the 4th quarter. Alliancebernstein L.P. now owns 85,875 shares of the medical analysis firm’s inventory price $4,252,000 after shopping for a further 3,174 shares over the last quarter. Lastly, Point72 Center East FZE acquired a brand new place in shares of Precise Sciences in the course of the 4th quarter price $1,525,000. 90.30% of the inventory is presently owned by hedge funds and different institutional traders.

Precise Sciences Firm Profile

(Get Ranking)

EXACT Sciences Corp. is a most cancers screening and diagnostics firm. The agency focuses on the early detection and prevention of some types of most cancers. It presents a non-invasive screening take a look at known as Cologuard for the early detection of colorectal most cancers and pre-cancer and Oncotype DX. The corporate was based on February 10, 1995, and is headquartered in Madison, WI.

See Additionally

The Fly logo

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)



Obtain Information & Scores for Precise Sciences Every day – Enter your e mail handle under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Precise Sciences and associated firms with MarketBeat.com’s FREE day by day e mail e-newsletter.

Johnson & Johnson (NYSE:JNJ) Holdings Lowered by Foundry Partners LLC

Mugen

ISWAP, Boko Haram: Why Tinubu govt, govs can’t dialogue with bandits – Shehu Sani

Mugen

US And Taliban Officials To Meet In Qatar To Discuss Security And Human Rights

Mugen